Non-Hodgkin Lymphoma Refractory/ Relapsed
Oncology·MeSH: Lymphoma, T-Cell, Cutaneous
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·3 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| cd19 t-hank | ImmunityBio, Inc. (IBRX) |
Frequently asked questions
How many drugs are in development for Non-Hodgkin Lymphoma Refractory/ Relapsed?
BioSniper tracks 1 drug in development for Non-Hodgkin Lymphoma Refractory/ Relapsed across 1 company.
How many clinical trials target Non-Hodgkin Lymphoma Refractory/ Relapsed?
There are 3 clinical trials targeting Non-Hodgkin Lymphoma Refractory/ Relapsed tracked by BioSniper.
What is the prevalence of Non-Hodgkin Lymphoma Refractory/ Relapsed?
The estimated prevalence of Non-Hodgkin Lymphoma Refractory/ Relapsed is approximately 56.0 per 100,000 population.
Deep-dive into Non-Hodgkin Lymphoma Refractory/ Relapsed
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis